Teoh, D., Ayeni, T., Rubatt, J., Adams, D., Grace, L., Starr, M., … Alvarez-Secord, A. (2010). Genomic SRC signature and SRC protein expression in ovarian cancers may predict response to the SRC inhibitor dasatinib. GYNECOLOGIC ONCOLOGY, 116(3), S151–S152.

Teoh, D., T. Ayeni, J. Rubatt, D. Adams, L. Grace, M. Starr, H. Dressman, A. Berchuck, and A. Alvarez-Secord. “Genomic SRC signature and SRC protein expression in ovarian cancers may predict response to the SRC inhibitor dasatinib.” GYNECOLOGIC ONCOLOGY 116, no. 3 (March 1, 2010): S151–52.

Teoh D, Ayeni T, Rubatt J, Adams D, Grace L, Starr M, et al. Genomic SRC signature and SRC protein expression in ovarian cancers may predict response to the SRC inhibitor dasatinib. GYNECOLOGIC ONCOLOGY. 2010 Mar 1;116(3):S151–2.

Teoh, D., et al. “Genomic SRC signature and SRC protein expression in ovarian cancers may predict response to the SRC inhibitor dasatinib.” GYNECOLOGIC ONCOLOGY, vol. 116, no. 3, ACADEMIC PRESS INC ELSEVIER SCIENCE, Mar. 2010, pp. S151–52.

Teoh D, Ayeni T, Rubatt J, Adams D, Grace L, Starr M, Dressman H, Berchuck A, Alvarez-Secord A. Genomic SRC signature and SRC protein expression in ovarian cancers may predict response to the SRC inhibitor dasatinib. GYNECOLOGIC ONCOLOGY. ACADEMIC PRESS INC ELSEVIER SCIENCE; 2010 Mar 1;116(3):S151–S152.